Company / Shareholders' Equity
Ovid Therapeutics Inc. Shareholders' Equity History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$68.2M
FY2025
5-year range
$68.2M / $179.7M
FY2022-FY2025
Trend
-22.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 3 consecutive years, from $180M in FY2022 to $68M in FY2025.
Based on SEC 10-K filings.
$68M in FY2025 with a 3-year CAGR of -27.6%.
Declined from $132M to $68M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -27.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Ovid Therapeutics Inc.'s shareholders' equity has declined for 3 consecutive years.
- 3-year CAGR of -27.6%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 22.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $68.2M | -22.3% |
| FY2024 | $87.8M | -33.6% |
| FY2023 | $132.3M | -26.4% |
| FY2022 | $179.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026